Jack Rubinlicht, DPM
Podiatrist · Phila, PANPI 1194703298
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Zimmer Biomet at 22.0% of the total. Reporting peaked in 2019 at $84 and has fallen 78.9% since, to $18 in 2025. That places this record below the midpoint for podiatrist clinicians in PA, where the typical reported total is $483.
Across 9 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$41
- Organogenesis Inc.$40
- Amgen$33
- Abbott$22
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$18
- Kerecis Limited$18
- plus $14 from 1 others
What the payments were for
- Food & beverage$185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 1 | $41 |
| Organogenesis Inc. | 2 | $40 |
| Amgen | 2 | $33 |
| Abbott | 1 | $22 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
| Kerecis Limited | 1 | $18 |
| AbbVie | 1 | $14 |
How this compares
$185 in reported general payments places this provider in the 30th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 55 | $1,154 |
| Ketoconazole | 30 | $678 |
| Cephalexin | 48 | $213 |
| Methylprednisolone | 34 | $150 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $127 |
| Azithromycin | 14 | $23 |
| Meloxicam | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Phila
- Mark HofbauerBelle Vernon$1.1M
- Daniel PerezPhiladelphia$434K
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
- John StarinskiPen Argyl$74K
- Kwasi KwaaduPhiladelphia$65K
- Luke CicchinelliPhiladelphia$62K
- James McGuirePhiladelphia$60K
- John SchelandClarks Summit$54K
- John LapelusaYork$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.